Biosystems Inc. focuses on developing and commercializing biological products
and technologies through leveraging its Core Base Business of developing
infectious disease antigens (virology) for sale to large diagnostic kit
The Company has reported Q4 and full-year F2013
results, with revenue for F2013 up 14% compared with F2012. Microbix
has provided updates on its thrombolytic drug Kinlytic™ (Urokinase)
as well as announcing patent litigation against Novartis Vaccines and
Read more in the Perspective here: Microbix Biosystems
is a primary source for professional investment research, focused on small- and
mid-cap companies. Our research and analysis is of institutional quality, and
has the potential for reaching millions of global investors through our
extensive electronic distribution network.
posts all its reports and articles on its website, eresearch.ca,
and subscription is FREE.
eResearch: Bob Weir, CFA,
Director of Research